Dr. Michael Agadjanyan is Vice President, Professor and Head of the Department of Molecular Immunology at the Institute for Molecular Medicine (IMM), Huntington Beach, California, a non-profit scientific research organization focused on chronic human diseases, including neurodegenerative disorders. He has more than 20 years of experience in the central nervous system field and 47 years of experience in immunology. Today, Dr. Agadjanyan discusses the licensing of IMM’s universal vaccine platform technology, MultiTEP, to a new biotechnology startup, Nuravax. The ultimate goal is the developmentand commercialization of MultiTEP-based vaccines for the prevention of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other life-threatening and deadly neurodegenerative diseases.
Dr. Agadjanyan is currently the Vice President, Professor and Head of the Department of Molecular Immunology at the Institute for Molecular Medicine, Huntington Beach, California and Adjunct Professor at the MiND Institute at UCI. He was formally a Visiting Professor at the Wistar Institute and at the University of Pennsylvania, Philadelphia, PA. Before coming to the US in 1991 he was a Professor at the Mechnikov’s Institute for Vaccines and Sera in Moscow at the Russian Academy of Medicine. He received his professional education in Moscow, earning both a Ph.D. and Doctor of Science (D.Sc.) degree. Dr. Agadjanyan’s training was in the area of molecular immunology, immunochemistry, and vaccine research. In these areas of science he has authored many patents, several book chapters and over one hundred and twenty scholarly articles on vaccines, cellular, and molecular immunologies, being published in top, peer-reviewed journals around the world. His research interests are in the area of the mechanisms of antigen presentation as applied to cancer and infectious disease as well as the development of vaccines and/or immunotherapeutics against cancers, Alzheimer’s disease, and Parkinson’s disease. In the last 25 years he has received numerous grants from the NIH as well as foundations such as the Susan G. Komen Foundation, and the Alzheimer’s Association supporting studies for the generation of humanized monoclonal antibodies and vaccines.